Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies

Area of Science:

• Oncology
• Pulmonology
• Clinical Trials

Background:

• Advances in diagnostics and treatments have improved survival for oligometastatic non-small cell lung cancer (NSCLC).
• Understanding of oligoprogressive disease biology has grown, yet definitions remain heterogeneous.
• Organizations like EORTC, ESTRO, and ASTRO have proposed definitions, but inconsistencies persist in clinical trials.

Purpose of the Study:

• To review definitions, treatment, and management of oligoprogressive disease in NSCLC.
• To discuss future directions and ongoing clinical trials for oligoprogressive NSCLC.
• To highlight the need for standardized criteria for oligoprogressive disease classification.

Main Methods:

• Literature review of definitions, treatment modalities, and management strategies.
• Analysis of recent findings and ongoing clinical trials.
• Discussion of tumor biology and subclassification of oligoprogressive disease.

Main Results:

• Significant advancements in diagnostic and treatment modalities for oligometastatic NSCLC have been achieved.
• Heterogeneity in definitions of oligoprogressive disease persists across studies and trials.
• Recognizing the varying risks of metastatic spread necessitates tailored management strategies.

Conclusions:

• A consensus on standardized criteria for defining oligoprogressive disease in NSCLC is urgently needed.
• Standardized definitions will facilitate meaningful comparisons between clinical studies.
• This consensus will pave the way for personalized treatment plans for heterogeneous oligoprogressive disease.